Cite
HARVARD Citation
Vaishampayan, U. et al. (n.d.). 877PFirst-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial. Annals of oncology. p. . [Online].